Eli Lilly at Goldman Sachs Conference: Navigating Policy and Growth

At the Goldman Sachs Global Healthcare Conference, Eli Lilly (LLY) addressed policy uncertainties, international strategies, and its financial outlook, emphasizing cost reduction and market expansion. The company is experiencing strong growth in the GLP-1 class with Zepbound and Mounjaro, expecting mid- to high single-digit price erosion but maintaining strong revenue guidance. Lilly is expanding internationally, particularly in China, India, and Mexico, while advancing clinical trials for orforglipron and Alzheimer's treatments; the impact of the MFN executive order on pricing remains uncertain.

Analysis

Eli Lilly, during its presentation at the Goldman Sachs 46th Annual Global Healthcare Conference, outlined a strategy focused on navigating policy uncertainties while capitalizing on significant growth opportunities, particularly within its GLP-1 franchise. The company reported robust uptake for Zepbound and Mounjaro, enabling it to regain market leadership in the GLP-1 class in Q1 2025. Financially, Eli Lilly anticipates mid- to high single-digit price erosion across its portfolio but maintains strong revenue guidance, supported by an 11 percentage point year-over-year expansion in operating margin in Q1 and a gross margin progressing towards 82%-83%. International expansion is a key priority, with Mounjaro now available in approximately 40 countries and notable progress in markets like China, India, and Mexico. The company's pipeline remains active, with critical data readouts for orforglipron and the SURPASS CVOT trial anticipated in Q3 2025, alongside ongoing development in Alzheimer's treatments such as Kesanla and preclinical asset TB3. While the impact of the MFN executive order on pricing remains uncertain, Eli Lilly reports consistent payer dynamics and is advancing initiatives like Lilly Direct, which includes telehealth services and direct shipment of Zepbound, to enhance patient access and manage compounding issues. The company's business development strategy favors early-stage, value-accretive tuck-in acquisitions, reflecting a disciplined approach to capital allocation and a focus on internal R&D productivity.

Key Decisions for Investors

• Investors should closely monitor the Q3 2025 clinical trial readouts for orforglipron and the SURPASS CVOT, as positive results could significantly bolster Eli Lilly's GLP-1 franchise and overall market valuation.
• The anticipated mid- to high single-digit price erosion and ongoing policy uncertainties, such as the MFN executive order, necessitate careful attention to the company's pricing power and payer access developments, particularly as contracting cycles conclude in the summer.
• Tracking the execution of international expansion strategies, especially in high-growth markets like China, India, and Mexico, and the commercial performance of newer assets beyond GLP-1s, such as Kesanla and Epclis, will be crucial for assessing the diversification and sustainability of Eli Lilly's growth.
• Eli Lilly's demonstrated R&D productivity, significant operating margin expansion (11 percentage points in Q1 YoY), and disciplined approach to tuck-in acquisitions are positive indicators; however, continued vigilance on these fronts is warranted to ensure sustained value creation against evolving market and regulatory landscapes.